About Us
Vision & Mission
We are passionate about improving health outcomes for individuals with GI disorders and autoimmune diseases.
We help clinicians to get their patients with complex diseases treated and in remission faster using precision-guided care.
Mike- Walther
Mike Walther serves as our President. Prior to Prometheus, Mike was most recently General Manager of Aries Pharmaceuticals having joined in 2017 to help establish the startup capabilities, commercial strategy…
Mike Walther
Mike Walther serves as our President. Prior to Prometheus, Mike was most recently General Manager of Aries Pharmaceuticals having joined in 2017 to help establish the startup capabilities, commercial strategy and launch of the company’s pharmaceutical and medical device portfolio of specialty gastroenterology products. Prior to Aries, Mike was with Prometheus, a Nestlé Health Science company, in a series of leadership roles across the company’s therapeutic and diagnostic businesses, concluding as Vice President of Commercial Development. Earlier in his career, Mike spent nearly two decades at Takeda Pharmaceuticals North America and TAP Pharmaceuticals (a Takeda and Abbott Laboratories joint venture) in key roles of increasing responsibility spanning Marketing, Sales, Market Access and Commercial Operations. Mike holds a BA in Biology from Ithaca College.
Thierry Dervieux, PharmD, PhD
Thierry Dervieux PharmD., PhD is our Chief Scientific Officer. Prior to joining Prometheus, Thierry was Chief Scientific Officer at Exagen Diagnostics where he spent a decade building the Avise® portfolio of testing solutions to…
Thierry Dervieux, PharmD, PhD
Thierry Dervieux PharmD, PhD is our Chief Scientific Officer. Prior to joining Prometheus, Thierry was Chief Scientific Officer at Exagen Diagnostics where he spent a decade building the Avise® portfolio of testing solutions to diagnose, prognose and monitor autoimmune rheumatic diseases, the success of which led to an initial public offering for the company. Prior to Exagen, Thierry led diagnostic and precision dosing development efforts at Cypress Biosciences, Proprius Pharmaceuticals (acquired by Cypress) and Prometheus Laboratories. Thierry is certified by the American Board of Clinical Chemistry in Clinical Chemistry and Molecular Diagnostics, and holds PharmD and PhD degrees from Claude Bernard University in Lyon, France. He also trained at St. Jude Children’s Research Hospital in Memphis, Tennessee. Thierry is the inventor or co-inventor on several patents and patent applications, has authored or co-authored over 60 publications.
Patricia Vasquez
Patricia Vasquez is our Senior Vice President of Commercial and Corporate Development. Patricia previously served as Vice President, Global Marketing, Business Development and Service for Inova Diagnostics, A Werfen Company, where she established technology…
Patricia Vasquez, MBA
Patricia Vasquez is our Senior Vice President of Commercial and Corporate Development. Patricia previously served as Vice President, Global Marketing, Business Development and Service for Inova Diagnostics, A Werfen Company, where she established technology and biomarker partnerships, and led the successful global launch of IVD systems and novel autoimmune disease diagnostic tests. Prior to Inova Diagnostics, Patricia was a co-founder of Proprius Pharmaceuticals, which was acquired by Cypress Bioscience, where she launched the Avise® rheumatology precision laboratory services and supported the co-promotion of Savella® (milnacipran). Previously, she held commercial roles of increasing responsibility at organizations such Prometheus Laboratories, Quest Diagnostics, Dura Pharmaceuticals and Quidel Corporation. She holds an MBA with a concentration in Marketing as well as a BA in Industrial/Organizational Psychology from San Diego State University.
Brian Littlefied
Brian Littlefield is the Senior Vice President of Information Services. Brian previously served at Exagen Diagnostics, where he established the IS function and led development and implementation of the…
Brian Littlefied
Brian Littlefield is the Senior Vice President of Information Services. Brian previously served at Exagen Diagnostics, where he established the IS function and led development and implementation of the information systems that enabled the company’s rapid growth. Prior to Exagen, Brian was with Prometheus Laboratories for sixteen years, having joined soon after its formation. During that time, he led the development and implementation of specialized systems to support proprietary diagnostic testing services and promotion of specialty therapeutics. Prior to that, Brian worked as a consultant with Deloitte and as the Director of Support Services at Quidel Corporation. Brian holds a BS in Biochemistry from Purdue University and an MBA from Pepperdine University.
Lei Lu
Lei Lu is our Senior Vice President of Finance and Accounting. Lei previously served as Executive Vice President, Finance for HUYABIO International, where he was responsible for leading the financial strategy, FP&A, tax, treasury and accounting operations. Prior to HUYABIO, he was the Senior Vice President…
Lei Lu is our Senior Vice President of Finance and Accounting. Lei previously served as Executive Vice President, Finance for HUYABIO International, where he was responsible for leading the financial strategy, FP&A, tax, treasury and accounting operations. Prior to HUYABIO, he was the Senior Vice President, Finance at ACEA Therapeutics (acquired by Sorrento Therapeutics) and ACEA Biosciences (acquired by Agilent). Before this, Lei was the Senior Vice President of Finance at Bird Rock Bio. He also held various senior financial management positions at Nokia, including head of finance/ global controller for their CDMA business unit. Preceding Nokia, he worked for Rockwell Automation, and Fiat Group (including Alfa Romeo UK, Case & New Holland) in various financial management positions. He has spent his professional career across the globe, working at companies in the US, UK, Italy, and China. Lei is a CPA. He earned his MBA from Leuven Business School at Katholieke Universiteit Leuven in Belgium and his BA in economics from Capital University of Economics and Business in China.
Mike- Walther
Mike Walther serves as our President. Prior to Prometheus, Mike was most recently General Manager of Aries Pharmaceuticals having joined in 2017 to help establish the startup capabilities, commercial strategy…
Mike Walther
Mike Walther serves as our President. Prior to Prometheus, Mike was most recently General Manager of Aries Pharmaceuticals having joined in 2017 to help establish the startup capabilities, commercial strategy and launch of the company’s pharmaceutical and medical device portfolio of specialty gastroenterology products. Prior to Aries, Mike was with Prometheus, a Nestlé Health Science company, in a series of leadership roles across the company’s therapeutic and diagnostic businesses, concluding as Vice President of Commercial Development. Earlier in his career, Mike spent nearly two decades at Takeda Pharmaceuticals North America and TAP Pharmaceuticals (a Takeda and Abbott Laboratories joint venture) in key roles of increasing responsibility spanning Marketing, Sales, Market Access and Commercial Operations. Mike holds a BA in Biology from Ithaca College.
Thierry Dervieux, PharmD, PhD
Thierry Dervieux PharmD., PhD is our Chief Scientific Officer. Prior to joining Prometheus, Thierry was Chief Scientific Officer at Exagen Diagnostics where he spent a decade building the Avise® portfolio of testing solutions to…
Thierry Dervieux, PharmD, PhD
Thierry Dervieux PharmD, PhD is our Chief Scientific Officer. Prior to joining Prometheus, Thierry was Chief Scientific Officer at Exagen Diagnostics where he spent a decade building the Avise® portfolio of testing solutions to diagnose, prognose and monitor autoimmune rheumatic diseases, the success of which led to an initial public offering for the company. Prior to Exagen, Thierry led diagnostic and precision dosing development efforts at Cypress Biosciences, Proprius Pharmaceuticals (acquired by Cypress) and Prometheus Laboratories. Thierry is certified by the American Board of Clinical Chemistry in Clinical Chemistry and Molecular Diagnostics, and holds PharmD and PhD degrees from Claude Bernard University in Lyon, France. He also trained at St. Jude Children’s Research Hospital in Memphis, Tennessee. Thierry is the inventor or co-inventor on several patents and patent applications, has authored or co-authored over 60 publications.
Patricia Vasquez
Patricia Vasquez is our Senior Vice President of Commercial and Corporate Development. Patricia previously served as Vice President, Global Marketing, Business Development and Service for Inova Diagnostics, A Werfen Company, where she established technology…
Patricia Vasquez, MBA
Patricia Vasquez is our Senior Vice President of Commercial and Corporate Development. Patricia previously served as Vice President, Global Marketing, Business Development and Service for Inova Diagnostics, A Werfen Company, where she established technology and biomarker partnerships, and led the successful global launch of IVD systems and novel autoimmune disease diagnostic tests. Prior to Inova Diagnostics, Patricia was a co-founder of Proprius Pharmaceuticals, which was acquired by Cypress Bioscience, where she launched the Avise® rheumatology precision laboratory services and supported the co-promotion of Savella® (milnacipran). Previously, she held commercial roles of increasing responsibility at organizations such Prometheus Laboratories, Quest Diagnostics, Dura Pharmaceuticals and Quidel Corporation. She holds an MBA with a concentration in Marketing as well as a BA in Industrial/Organizational Psychology from San Diego State University.
Brian Littlefied
Brian Littlefield is the Senior Vice President of Information Services. Brian previously served at Exagen Diagnostics, where he established the IS function and led development and implementation of the…
Brian Littlefied
Brian Littlefield is the Senior Vice President of Information Services. Brian previously served at Exagen Diagnostics, where he established the IS function and led development and implementation of the information systems that enabled the company’s rapid growth. Prior to Exagen, Brian was with Prometheus Laboratories for sixteen years, having joined soon after its formation. During that time, he led the development and implementation of specialized systems to support proprietary diagnostic testing services and promotion of specialty therapeutics. Prior to that, Brian worked as a consultant with Deloitte and as the Director of Support Services at Quidel Corporation. Brian holds a BS in Biochemistry from Purdue University and an MBA from Pepperdine University.
Lei Lu
Lei Lu is our Senior Vice President of Finance and Accounting. Lei previously served as Executive Vice President, Finance for HUYABIO International, where he was responsible for leading the financial strategy, FP&A, tax, treasury and accounting operations. Prior to HUYABIO, he was the Senior Vice President, Finance at ACEA Therapeutics (acquired by Sorrento Therapeutics) and ACEA Biosciences (acquired by Agilent). Before this, Lei was the Senior Vice President of Finance at Bird Rock Bio. He also held various senior financial management positions at Nokia, including head of finance/ global controller for their CDMA business unit. Preceding Nokia, he worked for Rockwell Automation, and Fiat Group (including Alfa Romeo UK, Case & New Holland) in various financial management positions. He has spent his professional career across the globe, working at companies in the US, UK, Italy, and China. Lei is a CPA. He earned his MBA from Leuven Business School at Katholieke Universiteit Leuven in Belgium and his BA in economics from Capital University of Economics and Business in China.
Lei Lu is our Senior Vice President of Finance and Accounting. Lei previously served as Executive Vice President, Finance for HUYABIO International, where he was responsible for leading the financial strategy, FP&A, tax, treasury and accounting operations. Prior to HUYABIO, he was the Senior Vice President, Finance at ACEA Therapeutics (acquired by Sorrento Therapeutics) and ACEA Biosciences (acquired by Agilent). Before this, Lei was the Senior Vice President of Finance at Bird Rock Bio. He also held various senior financial management positions at Nokia, including head of finance/ global controller for their CDMA business unit. Preceding Nokia, he worked for Rockwell Automation, and Fiat Group (including Alfa Romeo UK, Case & New Holland) in various financial management positions. He has spent his professional career across the globe, working at companies in the US, UK, Italy, and China. Lei is a CPA. He earned his MBA from Leuven Business School at Katholieke Universiteit Leuven in Belgium and his BA in economics from Capital University of Economics and Business in China.
Mike- Walther
Mike Walther serves as our President. Prior to Prometheus, Mike was most recently General Manager of Aries Pharmaceuticals having joined in 2017 to help establish the startup capabilities, commercial strategy…
Mike Walther
Mike Walther serves as our President. Prior to Prometheus, Mike was most recently General Manager of Aries Pharmaceuticals having joined in 2017 to help establish the startup capabilities, commercial strategy and launch of the company’s pharmaceutical and medical device portfolio of specialty gastroenterology products. Prior to Aries, Mike was with Prometheus, a Nestlé Health Science company, in a series of leadership roles across the company’s therapeutic and diagnostic businesses, concluding as Vice President of Commercial Development. Earlier in his career, Mike spent nearly two decades at Takeda Pharmaceuticals North America and TAP Pharmaceuticals (a Takeda and Abbott Laboratories joint venture) in key roles of increasing responsibility spanning Marketing, Sales, Market Access and Commercial Operations. Mike holds a BA in Biology from Ithaca College.
Thierry Dervieux, PharmD, PhD
Thierry Dervieux PharmD., PhD is our Chief Scientific Officer. Prior to joining Prometheus, Thierry was Chief Scientific Officer at Exagen Diagnostics where he spent a decade building the Avise® portfolio of testing solutions to…
Thierry Dervieux, PharmD, PhD
Thierry Dervieux PharmD, PhD is our Chief Scientific Officer. Prior to joining Prometheus, Thierry was Chief Scientific Officer at Exagen Diagnostics where he spent a decade building the Avise® portfolio of testing solutions to diagnose, prognose and monitor autoimmune rheumatic diseases, the success of which led to an initial public offering for the company. Prior to Exagen, Thierry led diagnostic and precision dosing development efforts at Cypress Biosciences, Proprius Pharmaceuticals (acquired by Cypress) and Prometheus Laboratories. Thierry is certified by the American Board of Clinical Chemistry in Clinical Chemistry and Molecular Diagnostics, and holds PharmD and PhD degrees from Claude Bernard University in Lyon, France. He also trained at St. Jude Children’s Research Hospital in Memphis, Tennessee. Thierry is the inventor or co-inventor on several patents and patent applications, has authored or co-authored over 60 publications.
Patricia Vasquez
Patricia Vasquez is our Senior Vice President of Commercial and Corporate Development. Patricia previously served as Vice President, Global Marketing, Business Development and Service for Inova Diagnostics, A Werfen Company, where she established technology…
Patricia Vasquez, MBA
Patricia Vasquez is our Senior Vice President of Commercial and Corporate Development. Patricia previously served as Vice President, Global Marketing, Business Development and Service for Inova Diagnostics, A Werfen Company, where she established technology and biomarker partnerships, and led the successful global launch of IVD systems and novel autoimmune disease diagnostic tests. Prior to Inova Diagnostics, Patricia was a co-founder of Proprius Pharmaceuticals, which was acquired by Cypress Bioscience, where she launched the Avise® rheumatology precision laboratory services and supported the co-promotion of Savella® (milnacipran). Previously, she held commercial roles of increasing responsibility at organizations such Prometheus Laboratories, Quest Diagnostics, Dura Pharmaceuticals and Quidel Corporation. She holds an MBA with a concentration in Marketing as well as a BA in Industrial/Organizational Psychology from San Diego State University.
Brian Littlefied
Brian Littlefield is the Senior Vice President of Information Services. Brian previously served at Exagen Diagnostics, where he established the IS function and led development and implementation of the…
Brian Littlefied
Brian Littlefield is the Senior Vice President of Information Services. Brian previously served at Exagen Diagnostics, where he established the IS function and led development and implementation of the information systems that enabled the company’s rapid growth. Prior to Exagen, Brian was with Prometheus Laboratories for sixteen years, having joined soon after its formation. During that time, he led the development and implementation of specialized systems to support proprietary diagnostic testing services and promotion of specialty therapeutics. Prior to that, Brian worked as a consultant with Deloitte and as the Director of Support Services at Quidel Corporation. Brian holds a BS in Biochemistry from Purdue University and an MBA from Pepperdine University.
Mark McKenna
Mr. McKenna serves as President, CEO and member of the board of Prometheus Biosciences. Prior to joining Prometheus Biosciences, Mr. McKenna was President & CEO of Salix Pharmaceuticals, a wholly owned subsidiary of Bausch Health Companies.
Mark McKenna
Mr. McKenna serves as President, CEO and member of the board of Prometheus Biosciences. Prior to joining Prometheus Biosciences, Mr. McKenna was President & CEO of Salix Pharmaceuticals, a wholly owned subsidiary of Bausch Health Companies. He joined Salix in March 2016 as the Senior Vice President and General Manager, responsible for the company’s gastrointestinal franchise. During his tenure, Mr. McKenna successfully led the company through a series of key strategic acquisitions, the launch of a number of new products, and delivered strong operating performance, with revenue increasing from $1.2B to $2B. Prior to joining Salix, Mr. McKenna spent more than a decade with Bausch + Lomb, most recently as Senior Vice President/General Manager of its U.S. Vision Care business. Prior to Bausch + Lomb, Mark held several roles of increasing responsibility at Johnson & Johnson. Mark holds a B.S. in Marketing from Arizona State University, an MBA from Azusa Pacific University and is a Fellow with the University of Pennsylvania, Wharton School of Business.
Jim Laur, JD
James Laur is Vice President, Intellectual Property and heads up Cedars-Sinai Technology Ventures reporting to the health system’s Chief Financial Officer. Mr. Laur’s primary responsibilities are focused on innovation, technology transfer and international business activities.
Jim Laur
James Laur is vice president, Intellectual Property and heads up Cedars-Sinai Technology Ventures reporting to the health system’s chief financial officer. Mr. Laur’s primary responsibilities are focused on innovation, technology transfer and international business activities. He drives new business development and investment opportunities involving innovation and technology-related activities at Cedars-Sinai and its global partners. Laur serves as co-executive sponsor of the Cedars-Sinai Accelerator Program and also represents Cedars-Sinai on the board of directors of some of its spinoff companies and other investments. He holds dual bachelor’s degrees, with honors, from UCLA in political science and philosophy. He earned his doctorate of law degree, cum laude, from the Boston College Law School.
Martin Hendrix
Martin joined NHSc in 2012 with the task of building a healthcare M&A capability for the group. Since then he has kept a relentless passion for growing the company’s portfolio through creative deals, ranging from large M&A transactions to small licensing deals and everything in between.
Martin Hendrix
Martin joined NHSc in 2012 with the task of building a healthcare M&A capability for the group. Since then he has kept a relentless passion for growing the company’s portfolio through creative deals, ranging from large M&A transactions to small licensing deals and everything in between.
Martin has a background in pharmaceutical R&D.
Prior to joining Nestlé he had a 14 year career at Bayer, starting out as a research chemist developing new medicines and later transitioning into M&A and corporate development. Martin likes the unique balance of NHSc’s approach to leverage the power of nutrition in both consumer health as well as medical nutrition and therapeutic products, with consumer deals like the acquisition of Atrium Innovations or the SpoonfulOne brand, and therapeutic deals like the acquisition of Zenpep, or innovation investments for topics such as food allergy, the human microbiome and metabolic health.
Martin is also a champion of NHSc’s venture investment strategy, which includes its partnership with Flagship Pioneering, as well as multiple direct investments in start-up companies. In connection with these investments, he has represented NHSc in the boards of Enterome, Microbiome Diagnostic Partners, Evelo, Kaleido, and Kintai.
William Sandborn, MD
Dr. William Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda California. He completed a gastroenterology fellowship at the Mayo Clinic in Rochester Minnesota in 1993. From 1993-2010…
William Sandborn, MD
Dr. William Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda California. He completed a gastroenterology fellowship at the Mayo Clinic in Rochester Minnesota in 1993. From 1993-2010, he was on the faculty of the Mayo Clinic, rising to Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations. In 2011 he joined the University of California San Diego (UCSD) as a Professor of Medicine, and from 2011-2021 he was Director of the IBD Center, and Chief of the Division of Gastroenterology at UCSD. Since 2021 he has continued as a Distinguished Professor of Medicine at UCSD. He was previously a co-founder of Santarus working directly with Scott Glenn, Stephan Targan & Gerry Proehl. Dr. Sandborn is also a co-founder and the chief medical officer of Shoreline Biosciences. He has published over 750 peer reviewed articles and is a member of the editorial board for the New England Journal of Medicine.
Dermot McGovern, MD, PhD
Dr. McGovern is a gastroenterologist and preeminent geneticist in the IBD field. Dr. McGovern completed his GI fellowship and obtained a PhD in complex disease genetics at the University of Oxford, England before moving to Cedars-Sinai …
Dermot McGovern, MD, PhD
Dr. McGovern is a gastroenterologist and preeminent geneticist in the IBD field. Dr. McGovern completed his GI fellowship and obtained a PhD in complex disease genetics at the University of Oxford, England before moving to Cedars-Sinai. Dr. McGovern is the Director of Translational Medicine at Cedars, co-Director of the Cedars-Sinai IBD repository (MIRIAD) and IBD Database and was recently appointed the Director of Precision Health at Cedars-Sinai. Dr. McGovern serves on both the Steering Committee of the NIDDK IBD Genetics Consortium, and on the Management Committee of the International IBD Genetics Consortium. Dr. McGovern is one of the founding members of Precision IBD, the predecessor of Prometheus Biosciences and serves as the consulting geneticist and provides input on the patient selection criteria.
Diane Mould, PhD
Dr. Diane Mould has spent 30 years as a pharmacokineticist in the industry specializing in population pharmacokinetic / pharmacodynamic modeling. Dr. Mould is the founder of Baysient LLC, a company that develops systems to individualize doses of drugs that are difficult to manage…
Diane Mould, PhD
Dr. Diane Mould has spent 30 years as a pharmacokineticist in the industry specializing in population pharmacokinetic / pharmacodynamic modeling. Dr. Mould is the founder of Baysient LLC, a company that develops systems to individualize doses of drugs that are difficult to manage. She is also the president of Projections Research, Inc., a consulting company offering pharmacokinetic and pharmacometric services.
She has advised most major pharmaceutical companies in clinical trial design, including Pfizer, BMS, Glaxo, Hoffmann-La Roche, Takeda, Amgen, and Janssen and has worked directly with healthcare centers including Memorial Sloan Kettering and the National Institutes of Health. Dr. Mould has extensive experience conducting population PK/PD analyses of many different agents, including hematopoietic agents, monoclonal antibodies, anti-cancer and anti-viral agents, antipsychotic, cardiovascular, and sedative/hypnotic agents.
She has published 96 peer-reviewed articles, 18 book chapters, made 124 national and international presentations. Dr Mould has also authored and presented 112 posters at national and international meetings. She is an adjunct professor at the University of Rhode Island, Ohio State University and the University of Florida, and teaches an annual class at the National Institutes of Health. She is a member of the editorial board for Journal of Pharmacokinetics and Pharmacodynamics, and Clinical Pharmacology and Therapeutics.
Adam Cheifetz, MD
Adam S. Cheifetz is the Director of the Center for Inflammatory Bowel Disease and Medical Director of Infusion Services at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is also Director of the Harvard Medical School Gastroenterology Clerkship Elective…
Adam Cheifetz, MD
Adam S. Cheifetz is the Director of the Center for Inflammatory Bowel Disease and Medical Director of Infusion Services at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is also Director of the Harvard Medical School Gastroenterology Clerkship Elective and Assistant Director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center.
Dr. Cheifetz graduated magna cum laude from Brown University before earning his M.D. from Cornell University Medical College. Dr. Cheifetz completed his internship and residency in Internal Medicine at Yale-New Haven Hospital and his fellowship in Gastroenterology at Yale University before serving as the Present-Levinson Fellow in Inflammatory Bowel Disease at the Mount Sinai Medical Center in New York City.
Dr. Cheifetz specializes in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. In addition to his clinical work, he is involved in multiple research projects relating to IBD and has published over 200 articles and chapters on the subject. His research currently focuses on optimizing the use of biologics through the proactive use of drug concentrations and antibodies and he has published extensively in this area. He is a fellow of the American Gastroenterological Association and American College of Gastroenterology.